ArticleIranian journal of microbiology2016
Emergence of CMY-2- and DHA-1-type AmpC β-lactamases in
Article in Iranian journal of microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 5 citations in OpenAlex.
- Disseminated multidrug-resistant Salmonella enterica serovar Dublin infection associated with plasmid-borne CMY-2 gene in a patient with travel to a farm in Mexico.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Genomic Diversity and Resistance Backgrounds of Enterobacteriaceae from Gulls and Coastal Environments.Genes · 2026Article
- Molecular characteristics of global β-lactamase-producing Enterobacter cloacae by genomic analysis.BMC microbiology · 2022Article
- Genomic Characterization of International High-Risk Clone ST410Antibiotics (Basel, Switzerland) · 2022Article
- Deadly Puppy Infection Caused by an MDRFrontiers in microbiology · 2020Article
- The Novel CarbaLux Test for Carbapenemases and Carbapenem Deactivating AmpC Beta-Lactamases.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe emergence of plasmid-mediated AmpC (pAmpC) β-lactamases conferring resistance to third-generation cephalosporins has become a major clinical concern worldwide. The aims of this study were to determine the prevalence of pAmpC-producing MATERIALS AND
methodsA total of 120 cefoxitin non-susceptible isolates of
resultsIn total, 20 (16.7%) isolates of
conclusionIn present study, we showed the first emergence of DHA-1 and CMY-2 types of pAmpC-producing
Indexed as
Identifiers
27928483PMC5139919W2502265526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.